Morphiceptin: Difference between revisions

| ImageSize =

| ImageAlt =

| IUPACName = (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide <ref name=ChemBase>{{cite web|title=Morphiceptin|url=http://www.chembase.com/cbid_119303.htm|work=Morphiceptin|publisher=ChemBase|accessdate=1 August 2011}}</ref>

| Section1 = {{Chembox Identifiers

| CASNo = 87777-29-5

| PubChem = 119303

| SMILES = }}

| Section2 = {{Chembox Properties

| Formula = C₂₈H₃₅N₅O₅

| MolarMass = 521.6

| Appearance =

| Density =

| MeltingPt =

| BoilingPt =

| Solubility = }}

| Section3 = {{Chembox Hazards

| MainHazards =

| FlashPt =

| Autoignition = }}

'''Morphiceptin''' is a tetrapeptide (Tyr-Pro-Phe-Pro-NH₂) that is a selective [[mu Opioid receptor|μ-opioid receptor]] [[agonist]]. It is derived from [[Casomorphin|β-casomorphin]] and has over 1000 times selectivity for μ receptors over [[delta Opioid receptor|δ opioid receptors]]. When administered intracerebroventricularly, morphiceptin had an analgesic ED₅₀ of 1.7 nmol per animal. The analgesic effects of morphiceptin were reversed by [[naloxone]], meaning that the analgesic effect is mediated by the μ opioid receptor.<ref name="Chang 1982">{{cite journal|last=Chang|first=K|title=Analgesic activity of intracerebroventricular administration of morphiceptin and β-casomorphins: Correlation with the morphine (μ) receptor binding affinity|journal=Life Sciences|month=May|volume=1982|issue=18|pages=1547-1551|doi=10.1016/0024-3205(82)90242-9|accessdate=1 August 2011}}</ref>

== References ==

{{Opioids}}

[[Category:Peptides]]

[[Category:Opioids]]